Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Amortization of Deferred Charges (2016 - 2018)

Avalo Therapeutics (AVTX) has disclosed Amortization of Deferred Charges for 5 consecutive years, with -$24342.0 as the latest value for Q4 2018.

  • For the quarter ending Q4 2018, Amortization of Deferred Charges fell 2434100.0% year-over-year to -$24342.0, compared with a TTM value of -$24342.0 through Sep 2019, down 107.44%, and an annual FY2018 reading of $302882.0, up 1387.34% over the prior year.
  • Amortization of Deferred Charges was -$24342.0 for Q4 2018 at Avalo Therapeutics, roughly flat from -$24342.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $246115.0 in Q2 2018 and bottomed at -$24342.0 in Q3 2018.
  • Average Amortization of Deferred Charges over 5 years is $48444.5, with a median of $36946.0 recorded in 2016.
  • Peak annual rise in Amortization of Deferred Charges hit 2990.73% in 2018, while the deepest fall reached 2434100.0% in 2018.
  • Year by year, Amortization of Deferred Charges stood at $44292.0 in 2014, then surged by 100.91% to $88989.0 in 2015, then plummeted by 68.34% to $28174.0 in 2016, then tumbled by 100.0% to -$1.0 in 2017, then plummeted by 2434100.0% to -$24342.0 in 2018.
  • Business Quant data shows Amortization of Deferred Charges for AVTX at -$24342.0 in Q4 2018, -$24342.0 in Q3 2018, and $246115.0 in Q2 2018.